摘要
目的了解单用噻托溴铵与噻托溴铵联合吸入糖皮质激素治疗哮喘-慢阻肺重叠综合征的作用。方法根据哮喘-慢阻肺重叠综合征(ACOS)诊断标准选取2014年6月—2016年6月该院收治的110例哮喘-慢阻肺重叠综合征患者作为观察对象,按照随机对照原则将其分为对照组和观察组,每组55例。对照组单用噻托溴铵治疗,观察组则采用噻托溴铵联合吸入糖皮质激素治疗,对比两组患者的治疗效果。结果治疗前,两组患者FEV1、RV/TLC、IC/TLC值差异无统计学意义(P>0.05);治疗后,观察组上述指标均明显优于对照组,并发症发生率低于对照组,两组比较差异有统计学意义(P<0.05);治疗后两组患者的ACT评分及CAT评分均较治疗前改善,但观察组的症状改善更加显著(P<0.05);观察组的急性发作次数减少(P<0.05)。结论噻托溴铵联合糖皮质激素吸入治疗哮喘-慢阻肺重叠综合征疗效显著,可有效促进患者的肺功能改善,降低并发症发生率。
Objective To explore the clinical curative effect of only used tiotropium combined with inhaled corticosteroids in the treatment of asthma-COPD overlap syndrome （ACOS） . Method According to ACOS diagnostic critria,110 cases of ACOS admitted to the hospital from June 2014 to June 2016 were selected and randomly divided into two groups, with 55 cases in each group. The patients in control group were given tiotropium treatment, the patients in observation group were given tiotropium combined with inhaled corticosteroids therapy, the therapeutic effect of two groups were analyzed. Results Before the treatment, two groups of patients with FEY 1 , RY/TLC , IC/TLC value differences had no statistical significance （P 〉 0. 05） . After treatment, the observation group of the above indicators were significantly better than the control group. The complication rate of observation group was lower than the control group, the difference was statistically significant （P 〈0. 05）. In the two groups after treatment the ACT of a grade and the CAT were improved, but the observation group of symptoms improved more significantly （P 〈0.05）. Compared the two groups, observation group of acute decreased （ P 〈 0. 05 ）. In addition, complications of observation group was obviously lower than the control group （P 〈0. 05） . Conclusion Tiotropium combined with inhaled corticosteroids therapy of asthma-COPD overlap syndrome curative effect is distinct, and can effectively promote the patient5 s lung function, reduce the incidence of complications. It has clinical value for reference.
